There are additional considerations that physicians need to consider when prescribing GLP-1s to patients with disabilities or ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

A new study adds on to the growing evidence of potential mental health benefits of GLP-1RAs, along with other benefits it ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...

GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro, have gained significant attention for their effectiveness in managing Type 2 diabetes and promoting weight loss. These medications work ...

GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...